Cytokine-secreting tumor cell vaccines (Q34046851)

30 July 2017

1 reference

title

Cytokine-secreting tumor cell vaccines (English)

1 reference

30 July 2017

Mach N

1

1 reference

PubMed ID

11007361

30 July 2017

Dranoff G

series ordinal

2

1 reference

30 July 2017

1 October 2000

1 reference

Current Opinion in Immunology

30 July 2017

1 reference

30 July 2017

12

1 reference

30 July 2017

5

1 reference

30 July 2017

571-575

1 reference

Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Differential tumor surveillance by natural killer (NK) and NKT cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Effect of interleukin 12 on tumor induction by 3-methylcholanthrene

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

In vivo natural killer cell activities revealed by natural killer cell-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

In vitro actions on hemopoietic cells of recombinant murine GM-CSF purified after production in Escherichia coli: comparison with purified native GM-CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1alpha and accumulation of dendritic cells at vaccination sites in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Induction of chemokine secretion and enhancement of contact-dependent macrophage cytotoxicity by engineered expression of granulocyte-macrophage colony-stimulating factor in human colon cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte respons

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

The central role of CD4(+) T cells in the antitumor immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

New paths in human cancer serology

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

Model predicting survival in stage I melanoma based on tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900144-8

7 January 2021

10.1016/S0952-7915(00)00144-8

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

11007361